CRISPR/Cas9 gene editing for curing sickle cell disease.
CRISPR/Cas9 gene editing for curing sickle cell disease.
复制标题
DOI:
10.1016/j.transci.2021.103060
复制
发表时间:
2021-03
期刊:
影响因子:
--
通讯作者:
Bao G
中科院分区:
文献类型:
--
作者:
Park SH;Bao G
Sickle cell disease (SCD) is the most common monogenic blood disorder marked by severe pain, end-organ damage, and early mortality. Treatment options for SCD remain very limited. There are only four FDA approved drugs to reduce acute complications. The only curative therapy for SCD is hematopoietic stem cell transplantation, typically from a matched, related donor. Ex vivo engineering of autologous hematopoietic stem and progenitor cells followed by transplantation of genetically modified cells potentially provides a permanent cure applicable to all patients regardless of the availability of suitable donors and graft-vs-host disease. In this review, we focus on the use of CRISPR/Cas9 gene-editing for curing SCD, including the curative correction of SCD mutation in β-globin (HBB) and the induction of fetal hemoglobin to reverse sickling. We summarize the major achievements and challenges, aiming to provide a clearer perspective on the potential of gene-editing based approaches in curing SCD.
登录
查看更多内容
影响因子:
8.8
作者:
Gundry MC;Brunetti L;Lin A;Mayle AE;Kitano A;Wagner D;Hsu JI;Hoegenauer KA;Rooney CM;Goodell MA;Nakada D
通讯作者:
Nakada D
影响因子:
7
作者:
Cho SW;Kim S;Kim Y;Kweon J;Kim HS;Bae S;Kim JS
通讯作者:
Kim JS
影响因子:
14.8
作者:
Bak RO;Dever DP;Porteus MH
通讯作者:
Porteus MH
影响因子:
46.9
作者:
Hendel A;Bak RO;Clark JT;Kennedy AB;Ryan DE;Roy S;Steinfeld I;Lunstad BD;Kaiser RJ;Wilkens AB;Bacchetta R;Tsalenko A;Dellinger D;Bruhn L;Porteus MH
通讯作者:
Porteus MH
影响因子:
17.3
作者:
Gaj, Thomas;Gersbach, Charles A.;Barbas, Carlos F., III
通讯作者:
Barbas, Carlos F., III